CLOs on the Move

Warner Chilcott, P.L.C.

www.wcrx.com

 
Warner Chilcott, P.L.C. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.wcrx.com
  • 100 Enterprise Dr Ste 280
    Rockaway, NJ USA '07866
  • Phone: 973.442.3200

Executives

Name Title Contact Details

Similar Companies

Mysite

Craft Health is a pharmaceutical drug delivery company that uses 3D printing technology to create personalized medicines and supplements for its customers.

Spinal Elements

Spinal Elements, Inc. is an innovative spine technology company that delivers new standards in spine surgery. Spinal Elements, previously Amendia.

Sol-Millennium Medical Group

SOL-MILLENNIUM is a vertically integrated global medical supply company with locations across the globe. We are one of the worlds largest manufacturers of needles, syringes, and blood collection devices with a comprehensive line of medical supplies fo...

Novabay

We are passionate about improving people`s daily lives by offering clinically proven solutions to common skin and eye care problems through digital channels, traditional domestic retailers, and international distributors. We are in the process of growing from a small single-product company into a profitable mid-sized multi-product company. Our leading product, Avenova®, is the only lid & lash solution that brings eyes back to life by setting the highest standards of purity and efficacy. We pioneered the use of hypochlorous acid in the eyecare space and intend on making Avenova a household name. Our motto is, “If you have eyes, you need Avenova!” We also recently acquired DERMAdoctor, LLC, a skincare company offering more than 30 dermatologist-developed skincare products. We plan to launch nine new products this year with the founder of DERMAdoctor doing well known media placements such as QVC.

Milestone Pharmaceuticals

Milestone was founded in 2005 with the underlying concept to base its drug development programs on clinically validated mechanisms of action in order to mitigate as much drug development risk as possible. The company has raised a total of $34 million in venture capital financing since 2006. At its founding, the company assembled a panel of leading pharmaceutical R&D executives (“drug hunters”) each with an average of 30 years experience in drug development. The drug hunters proposed NCE projects based on clinically proven science to form the basis of Milestone’s drug development programs. Milestone has a seasoned management team with experience in cardiovascular diseases, drug development and business start-ups as well as world-class advisory boards of key opinion leaders with significant expertise in cardiology, regulatory affairs, as well as formulation and drug development.